In the swiftly evolving landscape of gene therapy, antibody-oligonucleotide conjugates (AOCs) have emerged as a transformative platform primed to revolutionize targeted molecular delivery beyond the liver. Combining the exquisite cellular targeting nature of antibodies with the precise gene-modulating capabilities of oligonucleotides, AOCs exemplify a sophisticated therapeutic approach designed to overcome longstanding barriers in drug delivery. This hybrid modality strategically harnesses the specificity of antibodies to ferry nucleic acid payloads into cells, enabling refined regulation of genetic activity with minimized collateral effects—a feat that holds particular promise for addressing complex genetic disorders.
Unlike traditional antibody-drug conjugates (ADCs) that deliver cytotoxic agents to obliterate malignant cells, AOCs deploy nucleic acid sequences such as antisense oligonucleotides, small interfering RNAs, or splice-switching oligonucleotides. These payloads can selectively modulate gene expression, offering disease-modifying potential that transcends symptom management. This precision dramatically lowers off-target interactions, reducing adverse effects often associated with broader pharmacologic interventions. The ability of AOCs to enact gene-level corrections positions them at the forefront of next-generation therapeutics aimed at inherited and acquired genetic diseases.
Despite their remarkable promise, the clinical translation of AOCs is moderated by several critical challenges, paramount among them being the identification of optimal target receptors that facilitate effective cellular entry. The transferrin receptor 1 (TfR1), a gateway deeply explored for its natural role in iron uptake via receptor-mediated endocytosis, has been the primary focus of AOC development to date. Its robust endocytic capacity and widespread tissue expression make it an appealing vector for AOC delivery. Indeed, recent successes with TfR1-targeted AOCs in disorders like Duchenne muscular dystrophy (DMD) underscore its value, as evidenced by multiple candidates advancing into late-stage clinical trials.
However, TfR1 is far from a universal solution, as its expression profile and internalization dynamics limit the scope of AOC applicability. Consequently, ongoing research rigorously investigates alternative targets and seeks to refine antibody engineering strategies that enhance delivery efficiency. The endocytic kinetics of a receptor—its ability to internalize and traffic antibody-bound cargo to intracellular compartments—emerges as a pivotal determinant in this quest. Careful screening and validation of novel receptors with favorable endocytosis characteristics could unlock broader tissue targeting, especially for extrahepatic indications that have historically faced delivery bottlenecks.
Antibody format selection further intricate this therapeutic paradigm. Choices ranging from full-length immunoglobulins to smaller antibody fragments or engineered bispecific antibodies can profoundly influence AOC pharmacokinetics, tissue penetration, and internalization. Full-length IgGs tend to exhibit prolonged circulation half-lives but may face steric hindrance or suboptimal endocytic rates, whereas antibody fragments or bispecifics grant enhanced tissue accessibility and dual-targeting capabilities but often require modifications to stabilize their pharmacodynamic profiles. The delicate balance between molecular size, binding affinity, and immune system engagement is central to maximizing therapeutic windows.
Linker chemistry also assumes a crucial role in AOC design, where the conjugation interface between antibody and oligonucleotide dictates not only the stability of the construct in systemic circulation but also the controlled release of the nucleic acid payload within target cells. Various cleavable and non-cleavable linker motifs have been explored, each with nuances affecting the bioavailability and intracellular trafficking of the oligonucleotide. Optimizing linker properties to resist premature degradation while facilitating efficient cytosolic delivery remains a fundamental engineering challenge.
Parallel to antibody and linker optimization are advances in nucleic acid chemistry aimed at augmenting delivery and biological activity of oligonucleotide payloads. Chemical modifications such as phosphorothioate backbones, 2’-O-methyl, and locked nucleic acid (LNA) analogs bolster nuclease resistance, enhance binding affinity to target RNA, and modulate immune recognition. These strategic nucleotide alterations profoundly impact pharmacodynamics and contribute to the overall efficacy and safety profile of AOCs.
The cumulative insights from dissecting the structure-activity relationships across antibody engineering, linker design, and oligonucleotide modification illuminate a complex yet promising blueprint for fine-tuning AOC therapeutics. These intertwined parameters influence biodistribution, cellular uptake, endosomal escape, and ultimately the capacity to achieve potent gene modulation within diverse tissues.
Looking forward, the development trajectory of AOCs is poised to expand through innovative modalities. Emerging bispecific antibodies capable of simultaneously engaging multiple targets or receptors offer prospects for enhanced specificity and improved endocytic routing. Peptide conjugation strategies may complement antibody-mediated delivery by providing alternative or synergistic targeting mechanisms. Furthermore, the integration of cutting-edge gene editing tools such as CRISPR-Cas systems conjugated within AOC frameworks presents an avenue for permanent genetic correction rather than transient gene modulation.
Artificial intelligence (AI) and machine learning approaches are increasingly being employed to accelerate AOC design by predicting optimal antibody-oligonucleotide combinations, linker chemistries, and modification patterns. These computational tools analyze vast molecular data sets, enabling rational design and iterative refinement with unprecedented speed and accuracy. Such data-driven strategies promise to surmount current limitations, bringing bespoke AOC candidates from bench to bedside more rapidly.
The promise of AOCs to transcend the hepatic delivery confines that have historically hampered nucleic acid therapeutics marks a significant milestone in precision medicine. By leveraging antibody specificity and refined oligonucleotide design, these conjugates pave the way for systemic targeting of diseases affecting muscle, central nervous system, and other extrahepatic organs. Clinical strides exemplified by ongoing trials in muscular dystrophy highlight the maturation of this technology from experimental concept to viable therapeutic platform.
However, realizing the full potential of AOCs will require sustained interdisciplinary collaboration, integrating immunology, molecular biology, chemistry, and computational sciences. Equally important will be comprehensive clinical evaluation to understand long-term safety, optimal dosing regimens, and potential immunogenicity concerns arising from repeated administration.
In summary, antibody-oligonucleotide conjugates represent a compelling frontier in gene therapy, blending molecular precision with targeted delivery to surmount previously intractable challenges. The continued refinement of target selection, antibody engineering, linker chemistry, and nucleic acid modifications, empowered by AI-driven design and novel bioconjugation strategies, portends a transformative impact on the treatment landscape for genetic disorders. As this field matures, it is poised not only to expand therapeutic options but also to redefine paradigms of drug delivery and disease management in the twenty-first century.
Subject of Research: Antibody-oligonucleotide conjugates (AOCs) for targeted gene therapy and extrahepatic delivery strategies.
Article Title: Research progress and development strategies of antibody-oligonucleotide conjugates.
Article References:
Fan, W., Luan, W., Yu, W. et al. Research progress and development strategies of antibody-oligonucleotide conjugates. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00621-5
Image Credits: AI Generated
DOI: 25 May 2026
Keywords: Antibody-oligonucleotide conjugates, gene therapy, extrashepatic delivery, transferrin receptor 1, antibody engineering, linker chemistry, nucleic acid modification, bispecific antibodies, peptide conjugation, gene editing, artificial intelligence.
